{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:51:04Z","timestamp":1793317864604,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Osteogenesis imperfecta (OI), which is most often due to a collagen type 1 gene mutation, is characterized by low bone density and bone fragility. In OI patients, gender-related differences were reported, but data in the literature are not convergent. We previously observed that sclerostin antibody (Scl-Ab), which stimulates osteoblast Wnt pathway via sclerostin inactivation, improved spine and long-bone parameters and biomechanical strength in female oim\/oim mice, a validated model of human type 3 OI. Here, we wanted to highlight the effect of Scl-Ab on male oim\/oim bones in order to identify a possible distinct therapeutic effect from that observed in females. According to the same protocol as our previous study with female mice, male wild-type (Wt) and oim\/oim mice received vehicle or Scl-Ab from 5 to 14 weeks of age. Clinimetric and quantitative bone parameters were studied using X-rays, peripheral quantitative computed tomography, microradiography, and dynamic histomorphometry and compared to those of females. Contrary to Wt mice, male oim\/oim had significantly lower weight, snout\u2013sacrum length, and bone mineral content than females at 5 weeks. No significant difference in these clinimetric parameters was observed at 14 weeks, whereas male oim showed significantly more long-bone fractures than females. Scl-Ab improved bone mineral density and bone volume\/total volume ratio (BV\/TV) of vertebral body in Wt and oim\/oim, without significant difference between male and female at 14 weeks. Male vehicle oim\/oim had a significantly lower cortical thickness (Ct.Th) and BV\/TV of tibial diaphysis than female and showed a higher number of fractures at 14 weeks. Scl-Ab increased midshaft periosteal apposition rate in such a way that tibial Ct.Th of male oim\/oim was not significantly different from the female one at 14 weeks. The number of fractures was lower in male than female oim\/oim after 14 weeks of Scl-Ab treatment, but this difference was not significant. Nevertheless, Scl-Ab\u2013treated oim\/oim male and female mice remained smaller than the Wt ones. In conclusion, our results highlighted differences between male and female oim\/oim at 4 and 14 weeks of age, as well as some male-specific response of cortical bone to Scl-Ab. These gender-related particularities of oim\/oim should be considered when testing experimental treatments.<\/jats:p>","DOI":"10.3389\/fgene.2021.705505","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T08:10:33Z","timestamp":1628583033000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse"],"prefix":"10.3389","volume":"12","author":[{"given":"Micka\u00ebl","family":"Cardinal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Chretien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Lafont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ominsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Devogelaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Manicourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Behets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/ajcn\/80.5.1428","article-title":"Sex differences in the effect of body-composition variables on bone mass in healthy children and adolescents.","volume":"80","author":"Arabi","year":"2004","journal-title":"Am. J. Clin. Nutr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1196\/annals.1402.014","article-title":"Regulation of skeletal remodeling by the endocannabinoid system.","volume":"1116","author":"Bab","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41436-018-0307-y","article-title":"Longitudinal growth curves for children with classical osteogenesis imperfecta (types III and IV) caused by structural pathogenic variants in type I collagen.","volume":"21","author":"Barber","year":"2019","journal-title":"Genet. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00198-011-1742-7","article-title":"Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.","volume":"23","author":"Bargman","year":"2012","journal-title":"Osteoporos. Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.bone.2009.10.003","article-title":"Peak bone mineral density, lean body mass and fractures.","volume":"46","author":"Boot","year":"2010","journal-title":"Bone"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1007\/s11999-015-4268-z","article-title":"Are changes in composition in response to treatment of a mouse model of osteogenesis imperfecta sex-dependent?","volume":"473","author":"Boskey","year":"2015","journal-title":"Clin. Orthop. Relat. Res."},{"key":"B7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1359\/jbmr.1999.14.2.264","article-title":"The material basis for reduced mechanical properties in oim mice bones.","volume":"14","author":"Camacho","year":"1999","journal-title":"J. Bone Miner Res."},{"key":"B8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00223-019-00655-5","article-title":"Sclerostin- antibody treatment decreases fracture rates in axial skeleton and improves the skeletal phenotype in growing oim\/oim mice.","volume":"106","author":"Cardinal","year":"2020","journal-title":"Calcif. Tissue Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","article-title":"Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta.","volume":"124","author":"Cardinal","year":"2019","journal-title":"Bone"},{"key":"B10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1258\/la.2010.009085","article-title":"Isoflurane and sevoflurane provide equally effective anaesthesia in laboratory mice.","volume":"44","author":"Cesarovic","year":"2010","journal-title":"Lab. Anim."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/j.1600-0501.2008.01553.x","article-title":"Orthodontic loading of titanium miniplates in dogs: microradiographic and histological evaluation.","volume":"19","author":"Cornelis","year":"2008","journal-title":"Clin. Oral. Implants Res."},{"key":"B12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.apmr.2003.08.085","article-title":"Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up.","volume":"85","author":"Engelbert","year":"2004","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"B13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S8756-3282(02)00974-2","article-title":"Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta.","volume":"32","author":"Evans","year":"2003","journal-title":"Bone"},{"key":"B14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.matbio.2010.06.006","article-title":"Skeletal muscle weakness in osteogenesis imperfecta mice.","volume":"29","author":"Gentry","year":"2010","journal-title":"Matrix Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/jbmr.3473","article-title":"Skeletal response to soluble activin receptor Type IIB in mouse models of osteogenesis imperfecta.","volume":"33","author":"Jeong","year":"2018","journal-title":"J. Bone Miner Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1148\/rg.327125716","article-title":"Craniospinal abnormalities and neurologic complications of osteogenesis imperfecta: imaging overview.","volume":"32","author":"Khandanpour","year":"2012","journal-title":"Radiographics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3109\/17453674.2013.831321","article-title":"Bone mineral density in developing children with osteogenesis imperfecta: a longitudinal study with 9 years of follow-up.","volume":"84","author":"Kok","year":"2013","journal-title":"Acta Orthop."},{"key":"B19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.","volume":"25","author":"Li","year":"2010","journal-title":"J. Bone Miner Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1530\/EJE-14-0017","article-title":"Treatment of osteogenesis imperfecta in adults.","volume":"171","author":"Lindahl","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bone.2017.04.016","article-title":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.","volume":"101","author":"Little","year":"2017","journal-title":"Bone"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1002\/art.30385","article-title":"Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone.","volume":"63","author":"Marenzana","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1210\/jc.2013-1505","article-title":"New genes in bone development: what\u2019s new in osteogenesis imperfecta.","volume":"98","author":"Marini","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/jcp.49.8.627","article-title":"Causes of death in osteogenesis imperfecta.","volume":"49","author":"McAllion","year":"1996","journal-title":"J. Clin. Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Bone, Romosozumab in postmenopausal women with low bone mineral density.","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bone.2004.10.006","article-title":"Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.","volume":"36","author":"Misof","year":"2005","journal-title":"Bone"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJM198406283102602","article-title":"Osteogenesis imperfecta after the menopause.","volume":"310","author":"Paterson","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1016\/j.jbiomech.2008.09.028","article-title":"Bisphosphonate treatment in the oim mouse model alters bone modeling during growth.","volume":"41","author":"Rao","year":"2008","journal-title":"J. Biomech."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/s0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta.","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"B33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta.","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Mineral Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/ajmg.a.35327","article-title":"Analysis of skeletal dysplasias in the Utah population.","author":"Stevenson","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"key":"B36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","article-title":"Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb- immobilization rat model.","volume":"48","author":"Tian","year":"2011","journal-title":"Bone"},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.metabol.2017.06.001","article-title":"Osteogenesis imperfecta - A clinical update.","volume":"80","author":"Tournis","year":"2018","journal-title":"Metabolism"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000332228","article-title":"Osteogenesis imperfecta: a review with clinical examples.","volume":"2","author":"van Dijk","year":"2011","journal-title":"Mol. Syndromol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment.","author":"Van Dijk","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.bone.2012.03.007","article-title":"Ultra- structural defects cause low bone matrix stiffness despite high mineralization in osteogenesis imperfecta mice.","volume":"50","author":"Vanleene","year":"2012","journal-title":"Bone"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1182\/blood-2010-05-287565","article-title":"Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties.","volume":"117","author":"Vanleene","year":"2011","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.","volume":"96","author":"Ward","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11657-011-0054-z","article-title":"Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta.","volume":"6","author":"Wekre","year":"2011","journal-title":"Arch. Osteoporos."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s10439-013-0793-7","article-title":"Gender- dependence of bone structure and properties in adult osteogenesis imperfecta murine model.","volume":"41","author":"Yao","year":"2013","journal-title":"Ann. Biomed. Eng."},{"key":"B45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bonr.2018.06.008","article-title":"Loss of RANKL in osteocytes dramatically increases cancellous bone mass in the osteogenesis imperfecta mouse (oim).","volume":"9","author":"Zimmerman","year":"2018","journal-title":"Bone Rep."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.705505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T08:10:38Z","timestamp":1628583038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2021.705505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":45,"alternative-id":["10.3389\/fgene.2021.705505"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2021.705505","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"article-number":"705505"}}